116 related articles for article (PubMed ID: 14649897)
1. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists.
Tamamura H; Hiramatsu K; Mizumoto M; Ueda S; Kusano S; Terakubo S; Akamatsu M; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3663-9. PubMed ID: 14649897
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.
Tamamura H; Hiramatsu K; Kusano aS; Terakubo S; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3656-62. PubMed ID: 14649896
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
[TBL] [Abstract][Full Text] [Related]
4. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
5. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Tamamura H; Omagari A; Hiramatsu K; Gotoh K; Kanamoto T; Xu Y; Kodama E; Matsuoka M; Hattori T; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Jul; 11(14):1897-902. PubMed ID: 11459656
[TBL] [Abstract][Full Text] [Related]
6. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
7. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
8. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
9. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.
Tamamura H; Sugioka M; Odagaki Y; Omagari A; Kan Y; Oishi S; Nakashima H; Yamamoto N; Peiper SC; Hamanaka N; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Feb; 11(3):359-62. PubMed ID: 11212110
[TBL] [Abstract][Full Text] [Related]
10. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
11. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma.
Takenaga M; Tamamura H; Hiramatsu K; Nakamura N; Yamaguchi Y; Kitagawa A; Kawai S; Nakashima H; Fujii N; Igarashi R
Biochem Biophys Res Commun; 2004 Jul; 320(1):226-32. PubMed ID: 15207725
[TBL] [Abstract][Full Text] [Related]
12. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
Tamamura H; Hiramatsu K; Miyamoto K; Omagari A; Oishi S; Nakashima H; Yamamoto N; Kuroda Y; Nakagawa T; Otaka A; Fujii N
Bioorg Med Chem Lett; 2002 Mar; 12(6):923-8. PubMed ID: 11958995
[TBL] [Abstract][Full Text] [Related]
14. Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study.
Tamamura H; Omagari A; Hiramatsu K; Oishi S; Habashita H; Kanamoto T; Gotoh K; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem; 2002 May; 10(5):1417-26. PubMed ID: 11886804
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore-based small molecule CXCR4 ligands.
Narumi T; Tanaka T; Hashimoto C; Nomura W; Aikawa H; Sohma A; Itotani K; Kawamata M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem Lett; 2012 Jun; 22(12):4169-72. PubMed ID: 22579418
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of newly developed CXC-chemokine receptor 4 antagonists on the infection with feline immunodeficiency virus.
Mizukoshi F; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tamamura H; Oishi S; Fujii N; Tsujimoto H
J Vet Med Sci; 2009 Jan; 71(1):121-4. PubMed ID: 19194089
[TBL] [Abstract][Full Text] [Related]
18. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Boulais PE; Dulude D; Cabana J; Heveker N; Escher E; Lavigne P; Leduc R
Biochem Pharmacol; 2009 Dec; 78(11):1382-90. PubMed ID: 19631193
[TBL] [Abstract][Full Text] [Related]
19. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
